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Acute lung injury represents a wide spectrum of pathologic processes, the most severe end of
the spectrum being the acute respiratory distress syndrome. Reactive oxygen intermediates have
been implicated as important in the pathobiochemistry of acute lung injury. The endogenous
sources that contribute to the generation of reactive oxygen intermediates in acute lung injury are
poorly defined but probably include the molybdenum hydroxylases, NAD(P)H oxidoreductases,
the mitochondrial electron transport chain, and arachidonic acid-metabolizing enzymes. Our
laboratory has focused, in particular, on the regulation of two of these enzyme systems, xanthine
oxidoreductase (XDH/XO) and NAD(P)H oxidase. We observe that gene expression of XDH,XO is
regulated in a cell-specific manner and is markedly affected by inflammatory cytokines, steroids,
and physiologic events such as hypoxia. Posttranslational processing is also important in
regulating XDH/XO activity. More recently, the laboratory has characterized an NAD(P)H oxidase
in vascular cells. The cytochrome components ofthe oxidase, gp91 and p22, appear similar to the
components present in phagocytic cells that contribute to their respiratory burst. In human
vascular endothelial and smooth muscle cells, oncostatin M potently induces gp91 expression.
We believe that regulation of gp91 is a central controlling factor in expression of the vascular
NAD(P)H oxidase. In summary, the studies support the concept that the oxidoreductases of
vascular cells are expressed in a highly regulated and self-specific fashion. Environ Health
Perspect 106(Suppl 5):1235-1239 (1998). http.//ehpnetl.niehs.nih.gov/docs/1998/Suppl-5/
1235-1239hoidal/abstract.html
Key words: lung injury, xanthine oxidoreductase, NAD(P)H oxidase, gene regulation
The Clinical Problem
Acute lung injury contributes to the
morbidity and mortality of patients
throughout the world at tremendous
human and financial costs. It is a syn-
drome that includes pulmonary vasocon-
striction, inflammation, and increased
permeability ofboth the alveolar capillary
endothelium and epithelium, resulting in
arterial hypoxemia resistant to oxygen
therapy and diffuse infiltrates on chest
X-ray. This injury is associated most often
with sepsis, aspiration, pneumonia, mas-
sive trauma, or ischemt;a-reperfusion
injury and is frequentlytthe initial and
overriding component of the multiple
organ dysfunction syndrome. Acute lung
injury represents a wide spectrum of
pathologic processes, the most severe end of
the spectrum being the acute respiratory
distress syndrome (ARDS). Widely
reported figures place the incidence of
ARDS at approximately 150,000 cases per
year in the United States, although the fig-
ure is challenged and likely an overestimate
(1,2). The mortality from ARDS is high,
rangingfrom 30 to 90% in reported studies
[reviewed by Bernard et al. (2)]. Because of
this excessive morbidity and mortality, a
better understanding ofthepathobiology of
acute lung injury is necessary to design
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effective therapies or prophylactic measures




A number of independent pathogenic
mechanisms may cause acute lung injury.
One group ofinorganic compounds with
a high degree ofchemical reactivity that
has been implicated is the reactive oxygen
intermediates (ROI), including superox-
ide anion radical (02-, hydrogen perox-
ide (H202), hydroxyl radical, and
products of myeloperoxidase. ARDS
patients have increased production ofoxi-
dants in their lungs, as indicated by an
increased concentration of H202 in
expired air (3), and a deficiency in alveo-
lar epithelial lining fluid glutathione with
a greater percentage in the oxidized form
(4). In addition, some ofthe detrimental
effects of ROI are mediated through the
reaction of02--with nitric oxide to form
the potent oxidant OONO-. Potentially
toxic levels ofOONO- are present in the
lungs ofARDS patients (5).
Animal models provide strong support
for the critical involvement ofoxidants in
acute lung injury. The role has been
demonstrated in models of lung injury
from sepsis (6), viral pneumonia (7),
ischemia-reperfusion (8), hemorrhagic
shock, a systemic ischemia-reperfusion
insult (9), and hyperoxia (10). Antioxidant
enzymes or scavengers markedly reduce the
lung injury in these models.
Several mechanisms have been identified
by which oxidants can cause lung
dysfunction. Oxidants react with many
cellular components, oxidizing proteins,
lipids, DNA bases, enzymes for intermedi-
ary metabolism, and extracellular matrix
components including collagen and
hyaluronic acid (11-13). The production
of PGI2, isoprostanes,-and lipoxygenase
products is altered, causing defects in
platelet aggregation and vasorelaxation
(14,15). Depending on the extent ofoxi-
dant stress, cells exposed to ROI will
undergo apoptosis or necrosis (16). In
endothelial and epithelial cells, oxidant
injury may also impair macromolecular
barrier function, which leads to pul-
monary edema (17). As one possible
mechanism, 02 in posthypoxic endothe-
lial cells may directly affect the actin
cytoskeleton by changing the redox state
of actin regulatory proteins or of actin
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itself, thereby inducing actin polymer
formation (18). Finally, H202 and 02
can initiate production ofpotent chemo-
taxins (19) or can increase leukocyte adhe-
sion to endothelium via activation of
nuclear factor-kappa B-mediated transcrip-
tion ofintegrin genes (20,21). Thus, local-
ized production of ROI may initiate a
cascade that culminates in a fulminant
inflammatory response, tissue destruction,
and organ malfunction.
Source of Oxidants
Although evidence supporting a role for
oxidants in the pathobiochemistry ofacute
lung injury is substantial, key questions
that still need to be addressed include:
a) What are the endogenous sources of
ROI that initiate the lung injury, and
b) how are they regulated? The endoge-
nous sources that contribute to the genera-
tion ofROI in the lung are poorly defined
but likely include the molybdenum
hydroxylases (xanthine dehydrogenase/oxi-
dase [XDH/XO] and aldehyde oxidase),
NADPH or NADH oxidoreductases
(including the phagocytic cell oxidase
cytochrome P450 and nitric oxide
synthase), the mitochondrial electron
transport chain, and arachidonic acid-
metabolizing enzymes such as cyclooxyge-
nase. In the lung, the best studied sources
for ROI are XDH/XO and the NAD(P)H
oxidase ofphagocytic cells. During the
past 5 years our laboratory has concen-
trated on XDH/XO and more recently on
an incompletely described NAD(P)H oxi-
dase present in vascular cells. (Whether
NADH or NADPH is the preferred
substrate is not known.)
Xanthine Oxidoreductase
and Its Regulation
XDH, an NAD-dependent dehydrogenase,
catalyzes the final two reactions ofpurine
catabolism and as such is the rate-limiting
enzyme in their oxidative metabolism. The
enzyme is a homo-dimer with a subunit Mr
of about 150,000 daltons. Each subunit
contains four redox active centers: two iron
sulfur, one FAD, and one molybdopterin.
In mammalian species, XDH can be read-
ily converted to XO by reversible
sulfhydryl oxidation or by irreversible pro-
teolytic modification. The oxidation by
XDH ofhypoxanthine to xanthine and the
subsequent oxidation ofxanthine generates
the powerful antioxidant urate, which
directly scavenges ROI and chelates iron
(22). Ames and colleagues (22) proposed
that one mechanism for the lengthening
life-span and the decrease in age-specific
cancer rates during primate evolution may
be attributed to the high plasma levels of
urate that are 10-fold greater than in
lower mammals.
Juxtaposed to the potentially protective
physiologic function ofXDH in providing
urate as an antioxidant defense is the abil-
ity ofXO to generate 02- and H202 from
molecular oxygen. Originally proposed as
mediators ofischemia-reperfusion injury
(8), XO-derived ROI now have been
implicated in the pathogenesis ofcellular
injury in a wide variety ofpulmonary dis-
orders including viral pneumonia (23),
and following sepsis (24) or hemorrhagic
shock (25).
Sources of XDH/XO that mediate
injury include resident lung cells such as
endothelial and epithelial cells, both
important sources of the enzyme in some
species (26,27). Additionally, diverse
pathologic processes result in circulating
XDH/XO. XDH/XO released from tissues
into plasma can bind to sulfated gly-
cosoaminoglycans on vascular endothelial
cells to produce site-specific oxidant injury
to organs remote from the site of release
(28). As one example, XDH/XO-rich efflu-
ent from reperfused ischemic liver accumu-
lates in the lung in an enzymatically active
form (29). Importantly, patients with
ARDS (3), viral infections (30), or tourni-
quet-related ischemia-reperfusion injury
have markedly increased levels ofplasma
XDH/XO (31). These observations provide
a possible explanation for lung injury
followingaperipheral insult.
Most studies investigating the role of
XDH/XO in disease pathogenesis have
applied the axiom that the significance of
XDH/XO as a mechanism for generation
ofROI in tissues is determined simply by
the rate of conversion ofXDH to XO.
However, recent molecular and biochemi-
cal approaches have provided important
new insights into the regulation of
XDH/XO that may apply not only to
ischemia-reperfusion but also to inflam-
matory disorders. Thus, besides the sim-
ple conversion ofXDH to XO, additional
mechanisms may regulate the enzyme
leading to enhanced ROI generation.
Characterization of the cDNA for
XDH/XO by Amaya (32) has made
possible the evaluation of the transcrip-
tional regulation ofXDH/XO. Our labo-
ratory first demonstrated transcriptional
regulation ofthe enzyme and found that
interferon gamma (IFN-y) selectively
induced gene activation in pulmonary
microvascular cells and in rat lungs in
vivo (26). We subsequently demonstrated
transcriptional regulation ofXDH/XO in
epithelial cells bycytokines and steroids in
a pattern analogous to the profile seen by
acute phase reactants in response to
injury, trauma, or infection (33).
Although the acute phase response is
thought to protect the host, the role of
XDH/XO upregulation as part of this
reaction could be deleterious because of
the increased generation of ROI. More
recently, transcriptional activation of
XDH/XO has been shown in response to
hypoxia (34) or after lipopolysaccharide
(LPS) exposure in vivo (35). The impor-
tance of these studies rests on their
demonstration that XDH/XO gene
expression is regulated in a cell-specific
manner and is markedly affected by
inflammatory cytokines, steroids, and
physiologic events such as hypoxia.
A second important advance is the
information about posttranscriptional and
posttranslational regulation ofXDH/XO.
We have demonstrated recently that
hypoxia not only transcriptionally regulates
XDH/XO, as suggested by Hassoun and
colleagues (34), but also enhances enzyme
activity by as yet undefined posttranslational
processes that do not involve conversion of
XDH toXO (36). Posttranscriptional regu-
lation by iron (37) and posttranslational
regulation by nitric oxide (38) have also
been established. Moreover, the recent evi-
dence that human XDH/XO can undergo
activation-deactivation cydes at the molyb-
denum redoxcenter (39) fiurtheremphasizes
thepotential importance ofposttranslational
regulation ofXDH/XO.
A third important advance is the
evidence that XDH/XO acts not only on
purines but also on reducing substrates
including NADH with resultant O2 for-
mation. Recent studies indicate that
XDH/XO can oxidize NADH, producing
02-- at 0.23 pmol/min/mg (40). These
findings suggest an alternative mechanism
for ischemia-induced reperfusion injury. By
this alternativemechanism, ischemia elevates
intracellular NADH levels, which leads to
02- generation byXDH/XO on reoxygen-
ation oftissues. This mechanism does not
depend on XDH-to-XO conversion (a con-
troversial issue). We believe that the NADH
oxidation does not involve the molyb-
denum center ofthe enzyme (Figure 1) and
therefore would not be inhibited by
purine analogs such as allopurinol or
oxypurinol, or by a supplementation with
tungstate. This observation is noteworthy
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in light ofthe recent demonst
uncharacterized NADH ox
important source ofROI in lu
reperfusion injury (41,42) an
ing increase in cellular NADI
during ischemia.
In summary, recent in
indicates that XDH/XO is r(
both transcriptional and postt
events possibly acting in
increase the enzyme's ability
ROI, and that its ability to ge
may not depend solely on the h
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Figure 1. Electron transfer pathways M
as an NADH oxidase. Mo, molybdeni
sulfide.
ration ofan (known as Rac2 in humans), rho-GDI, and
idase as an p4OPhox. In neutrophils, oxidase is activated
[ng cells and by assembly ofthe cytosolic proteins with
Ld the strik- the membrane components. Heritable
H occurring defects ofeither gp91, p22, p47, or p67 are
the basis for CGD, a disorder ofwhite cell
iformation function characterized by recurrent, severe,
egulated by bacterial and fungal infections. The genes
translational encoding the different phagocyte
concert to NAD(P)H oxidase components have been
to generate cloned and respective cDNA probes gener-
mnerate ROI ated, thus allowing studies on the expres-
Lalf-reductive sion and localization ofdifferent mRNA
olybdenum transcripts in cells and tissues.
During the past few years, evidence has
been accumulating that a similar enzyme
complex is present and exerts a variety of
functions in nonphagocytic cells. Both the
icture and endothelium and vascular smooth muscle
dase comes contain a membrane-bound oxidase that
hils in which uses NADH and NADPH as substrates for
ie respiratory electron transfer to 02 that appears similar
;idal activity to the NAD(P)H oxidase of neutrophils
se is a multi- (44-46). In cultured vascular smooth
ites O2- in muscle cells, the oxidase is a significant
using elec- source ofO2--formation (47). For exam-
[reviewed by ple, in calfpulmonary and coronary artery
expressed at smooth muscle, this oxidase accounts for
eO2 is the the majority of the 02-- generated
her reactive (45,48). Importantly, it uses a cytochrome
l and fungi. b558 electron transport system (45). There
mbrane pro- are, however, important differences
ether form a between the vascular oxidase and the neu-
ox midpoint trophil oxidase. These include the delayed
duced minus time course for activation, low output, and
f558. Based in some studies, the preference for NADH
mnic granulo- rather that NADPH of the vascular oxi-
two cystolic dase. The low-output property does not
[so essential. detract from the importance ofthe vascu-
Ponents that lar oxidase as an initiator ofendothelial or
-tivity ofthe smooth muscle dysfunction, and it may
e have been function as a signaling system for gene
[1 G protein activation (49).
To date, there has not been a
comprehensive molecular characterization
Hypoxanthine of the vascular NAD(P)H oxidase. Ushio-
urate Fukai and co-workers (50) have provided
evidence that p22 is a critical component
ofthe 02-generating vascular NAD(P)H
oxidase and suggest a central role for this
oxidase system in vascular hypertrophy.
However, it is unlikely that p22 serves as
a complete oxidase on its own, as it can
function only as a one-electron acceptor
and lacks substrate-binding sites and
flavin-binding sites (43). The other
subunit of the electron transport element
of the vascular NAD(P)H oxidase has
vithinXDH:XDH been more elusive. Recent immuno-
um; FeS, iron(lj) histochemical studies have suggested
expression of gp91 in vascular smooth
muscle cells (46), but this has not been a
consistent finding (51). Because the
substrate specificity of the neutrophil
NAD(P)H oxidase resides in gp91, it is
likely that it is this subunit that det-
ermines the unique properties of the
vascular oxidase.
To define the components responsible
for the NAD(P)H oxidase activity in
human vascular cells, we screened a human
umbilical vein endothelial cell (HUVEC)
cDNA library (in lgt 1l; Clontech, Palo
Alto, CA) using probes for gp91, p22, p47,
and p67. The probes were generated by
polymerase chain reaction using primers
designed from phagocyte sequences. To
date we have isolated from the HUVEC
library a full-length p22 cDNA, a 1200-bp
fragment ofgp91, and a 500-bp fragment
ofp67. We have also amplified by reverse
transcriptase-polymerase chain reaction
(RT-PCR) a 350-bp fragment from
HUVEC mRNA using primers specific for
p47 but have not as yet isolated a p47 clone
by library screening. These fragments have
been sequenced and are identical to their
neutrophil counterparts. Likewise, in frag-
ments derived from pulmonary artery
smooth muscle cells (PASMC) by RT-
PCR, we have sequenced approximately
300 bp from the translated region ofp22,
p47, and p67, and, as in the case of
endothelial cells, the sequences are identical
to their phagocytic counterparts.
To initiate studies to define the factors
that determine cell-specific gene expression,
we used RT-PCR to identify transcripts
for the NAD(P)H oxidase components in
isolated endothelial and vascular smooth
muscle cells. We have consistently found
transcripts for p22, p47, and p67 in
HUVEC. Transcripts for gp91 were usu-
ally not detected or were detected at low
levels in HUVEC in the absence of an
agonist. Transcripts for p22 were also
detected in human aortic and lung
microvascular endothelial cells, and
intestinal and PASMC. Using Northern
blot analysis, we detected p22 but not
gp91 in HUVEC and PASMC. Our
interpretation is that under basal condi-
tions, p22 transcripts are expressed in sub-
stantially greater amounts than gp91
transcripts in HUVEC and PASMC.
Recently, we have initiated studies to
evaluate factors that may regulate the
expression ofthe NAD(P)H oxidase com-
ponents. We focused on the effects of
cytokines and hypoxia because oftheir rel-
evance to ARDS. Addition ofLPS, tumor
necrosis factor a, IFN-,y, or interleukin-l1
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neither induced gp91 gene expression in
HUVEC or PASMC nor changed the level
ofmRNA transcripts for the other three
components. However, oncostatin M
(OSM) potently induced gp91 in HUVEC
and PASMC. The induction of gp91
required 8- to 24-hr exposure to OSM and
was blocked by addition ofcycloheximide
(5 pg/ml), suggesting a requirement for
intermediate protein synthesis. At variance
with the induction ofmRNAtranscripts for
gp91 by OSM, there was no induction of
the other NAD(P)H oxidase components
by any ofthe cytokines. This suggests that
whereas gp91 is inducible in HUVEC and
PASMC, p22, p47, and p67 are constitu-
tively expressed in these cells. On the
basis of these findings, we propose that
regulation ofgp91 is a central controlling
factor in the expression of the vascular
NAD(P)H oxidase.
In summary, recent studies support the
concept that the oxidoreductases ofvascular
cells are expressed in a highly regulated and
cell-specific fashion. The regulation ofthese
enzyme systems is likely to have a profound
impact on their role in acute lung injury.
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